Pub Date : 2025-07-17eCollection Date: 2025-07-01DOI: 10.1515/jbcpp-2025-0084
Saurav Misra, Manmeet Kaur, Jayant Kumar Kairi
Objectives: This study will identify strengths and weaknesses of ADR reporting forms of study countries.
Methods: This was an observational study conducted at the Department of Pharmacology at Kalpana Chawla Government Medical College, Karnal. We obtained the WHO-UMC adverse event reporting guidance document for designing the ADR form for member countries. We similarly collected and analysed ADR forms from Australia, Canada, India, South Africa, the UK, and the US. Data fields were grouped into different subgroups.
Results: An analysis of ADR reporting forms from six countries revealed a total of 70 data fields. The US-FDA's FORM 3500 has the most fields at 50 (71 %), followed by India's CDSCO with 42 fields (60 %). According to WHO-UMC recommendations, Canada and Australia have the highest number of suggested fields at 10 (83 %). All forms were one page long except for the US-FDA's, which is five pages.
Conclusions: Improving patient feedback and organisational engagement is essential to raise awareness of the reporting system. A proposed generic ADR form provides detailed information for causality assessment and could serve as a basis for a standard global reporting form.
{"title":"A critical comparison of pharmacovigilance reporting forms in six countries with the WHO-UMC recommendations (form of the form).","authors":"Saurav Misra, Manmeet Kaur, Jayant Kumar Kairi","doi":"10.1515/jbcpp-2025-0084","DOIUrl":"10.1515/jbcpp-2025-0084","url":null,"abstract":"<p><strong>Objectives: </strong>This study will identify strengths and weaknesses of ADR reporting forms of study countries.</p><p><strong>Methods: </strong>This was an observational study conducted at the Department of Pharmacology at Kalpana Chawla Government Medical College, Karnal. We obtained the WHO-UMC adverse event reporting guidance document for designing the ADR form for member countries. We similarly collected and analysed ADR forms from Australia, Canada, India, South Africa, the UK, and the US. Data fields were grouped into different subgroups.</p><p><strong>Results: </strong>An analysis of ADR reporting forms from six countries revealed a total of 70 data fields. The US-FDA's FORM 3500 has the most fields at 50 (71 %), followed by India's CDSCO with 42 fields (60 %). According to WHO-UMC recommendations, Canada and Australia have the highest number of suggested fields at 10 (83 %). All forms were one page long except for the US-FDA's, which is five pages.</p><p><strong>Conclusions: </strong>Improving patient feedback and organisational engagement is essential to raise awareness of the reporting system. A proposed generic ADR form provides detailed information for causality assessment and could serve as a basis for a standard global reporting form.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"285-294"},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-11eCollection Date: 2025-09-01DOI: 10.1515/jbcpp-2024-0211
Milad Ashrafizadeh
The application of natural occurring compounds in the treatment of human diseases has been increased in the recent decades due to the biocompatibility and pleiotropic impacts of these agents along with significant health-promoting effects. Among them, resveratrol has been shown to be of importance, since it can exert various biological and pharmacological activities. Moreover, resveratrol generally demonstrates good biosafety and biocompatibility that can further improve its application in clinical studies. In terms of biological activities, the antioxidant and anti-inflammatory activities of resveratrol has been of importance and they are useful in the prevention of diabetes and neurological diseases. The antioxidant activity of resveratrol can result from its function in enhancing levels of antioxidant factors such as catalase and superoxide dismutase, and reduction in ROS levels. Moreover, resveratrol can reduce inflammation and downregulate related pathways such as NF-κB. Beyond this, resveratrol has been shown to be beneficial in the treatment of human diseases such as diabetes mellitus, cancer (suppressing tumorigenesis or acting as chemopreventive agent) and alleviation of neurological diseases, among others. Such protective impacts of resveratrol would be discussed in the current review with a focus on underlying molecular factors. In addition, nanoparticles have been significantly applied in the treatment of human disease through delivery of resveratrol and since pharmacokinetic profile of resveratrol is poor, the application of delivery systems can accelerate therapeutic index of this natural product. However, clinical application of resveratrol-loaded nanoparticles in the clinical level relies on the biocomaptibility and safety of these structures along with their efficacy.
{"title":"<b>Therapeutic potential of</b> r<b>esveratrol:</b> n<b>ovel</b> b<b>iological and</b> p<b>harmacological</b> p<b>erspectives</b>.","authors":"Milad Ashrafizadeh","doi":"10.1515/jbcpp-2024-0211","DOIUrl":"10.1515/jbcpp-2024-0211","url":null,"abstract":"<p><p>The application of natural occurring compounds in the treatment of human diseases has been increased in the recent decades due to the biocompatibility and pleiotropic impacts of these agents along with significant health-promoting effects. Among them, resveratrol has been shown to be of importance, since it can exert various biological and pharmacological activities. Moreover, resveratrol generally demonstrates good biosafety and biocompatibility that can further improve its application in clinical studies. In terms of biological activities, the antioxidant and anti-inflammatory activities of resveratrol has been of importance and they are useful in the prevention of diabetes and neurological diseases. The antioxidant activity of resveratrol can result from its function in enhancing levels of antioxidant factors such as catalase and superoxide dismutase, and reduction in ROS levels. Moreover, resveratrol can reduce inflammation and downregulate related pathways such as NF-κB. Beyond this, resveratrol has been shown to be beneficial in the treatment of human diseases such as diabetes mellitus, cancer (suppressing tumorigenesis or acting as chemopreventive agent) and alleviation of neurological diseases, among others. Such protective impacts of resveratrol would be discussed in the current review with a focus on underlying molecular factors. In addition, nanoparticles have been significantly applied in the treatment of human disease through delivery of resveratrol and since pharmacokinetic profile of resveratrol is poor, the application of delivery systems can accelerate therapeutic index of this natural product. However, clinical application of resveratrol-loaded nanoparticles in the clinical level relies on the biocomaptibility and safety of these structures along with their efficacy.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"301-318"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144600557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michele Musone, Stefano Chianese, Ciro Chervino, Antonio Madonna, Tiziana Rotunno
{"title":"Future therapeutic perspectives of BCG therapy for bladder cancer: an evolving horizon.","authors":"Michele Musone, Stefano Chianese, Ciro Chervino, Antonio Madonna, Tiziana Rotunno","doi":"10.1515/jbcpp-2025-0106","DOIUrl":"10.1515/jbcpp-2025-0106","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"243-245"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-11eCollection Date: 2025-07-01DOI: 10.1515/jbcpp-2024-0234
Dalia O Saleh, Ahmed A Sedik
Heart failure (HF) represents the final manifestation of various cardiovascular diseases, emerging as a significant global health challenge that impacts over 20 million individuals worldwide. This review provides a comprehensive overview of the latest pharmacological agents developed to address HF, focusing on their effectiveness in alleviating symptoms associated with the condition. It highlights the critical necessity for a more profound understanding of the multifaceted processes and pathways that contribute to HF pathogenesis. The methodology employed in this review demonstrates encouraging outcomes from numerous pharmaceutical agents evaluated for their ability to relieve HF symptoms, showcasing their effectiveness in improving patient experiences. However, a significant gap remains in tackling the fundamental issues underlying HF. The findings emphasize the intricate nature of HF and the obstacles faced in creating therapies that extend beyond mere symptomatic management. Currently, the predominant approach to HF treatment involves targeting the underlying mechanisms of the disease and addressing related neurohumoral imbalances. Despite the growing arsenal of treatments available for HF, patient outcomes continue to be suboptimal. Therefore, this review aims to illuminate potential therapeutic targets for more effective management strategies for HF, ultimately striving to enhance patient prognosis and quality of life.
{"title":"Insight into novel therapeutic targets in heart failure: a comprehensive review.","authors":"Dalia O Saleh, Ahmed A Sedik","doi":"10.1515/jbcpp-2024-0234","DOIUrl":"10.1515/jbcpp-2024-0234","url":null,"abstract":"<p><p>Heart failure (HF) represents the final manifestation of various cardiovascular diseases, emerging as a significant global health challenge that impacts over 20 million individuals worldwide. This review provides a comprehensive overview of the latest pharmacological agents developed to address HF, focusing on their effectiveness in alleviating symptoms associated with the condition. It highlights the critical necessity for a more profound understanding of the multifaceted processes and pathways that contribute to HF pathogenesis. The methodology employed in this review demonstrates encouraging outcomes from numerous pharmaceutical agents evaluated for their ability to relieve HF symptoms, showcasing their effectiveness in improving patient experiences. However, a significant gap remains in tackling the fundamental issues underlying HF. The findings emphasize the intricate nature of HF and the obstacles faced in creating therapies that extend beyond mere symptomatic management. Currently, the predominant approach to HF treatment involves targeting the underlying mechanisms of the disease and addressing related neurohumoral imbalances. Despite the growing arsenal of treatments available for HF, patient outcomes continue to be suboptimal. Therefore, this review aims to illuminate potential therapeutic targets for more effective management strategies for HF, ultimately striving to enhance patient prognosis and quality of life.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"247-262"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144266277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-03eCollection Date: 2025-07-01DOI: 10.1515/jbcpp-2025-0089
Rita Tavarozzi, Anna Lombardi, Ferdinando Scarano, Laura Staiano, Gerardo Trattelli, Michela Farro, Alessia Castellino, Carmine Coppola
Introduction: Superficial lymph node (LN) enlargement is a common ultrasonographic finding and can be associated with a broad spectrum of conditions, from benign reactive hyperplasia to malignant lymphoproliferative disorders (LPDs). LPDs, which include various hematologic malignancies affecting lymphoid tissue, present with diverse immune-morphological and clinical features, making differentiation from other malignant causes of lymphadenopathy challenging.
Content: Radiologic assessment is crucial in characterizing lymphadenopathy, with ultrasonography serving as a noninvasive and widely available imaging modality. High-resolution ultrasound allows the evaluation of key features such as LN size, shape, border definition, echogenicity, and the presence of abnormal cortical thickening, loss of the fatty hilum, or altered vascular patterns, which aid in distinguishing benign from malignant processes.
Summary: This review aims to describe the ultrasonographic characteristics of lymphadenopathy, offering essential diagnostic insights to differentiate malignant disorders, particularly LPDs. We will discuss standard ultrasound techniques, including grayscale imaging and Doppler ultrasound, and explore more advanced methods such as contrast-enhanced ultrasound (CEUS), elastography, and artificial intelligence-assisted imaging, which are gaining prominence in LN evaluation.
Outlook: By highlighting these imaging modalities, we aim to enhance the diagnostic accuracy of ultrasonography in lymphadenopathy assessment and improve early detection of LPDs and other malignant conditions.
{"title":"Lymph node ultrasound in lymphoproliferative disorders: clinical characteristics and applications.","authors":"Rita Tavarozzi, Anna Lombardi, Ferdinando Scarano, Laura Staiano, Gerardo Trattelli, Michela Farro, Alessia Castellino, Carmine Coppola","doi":"10.1515/jbcpp-2025-0089","DOIUrl":"10.1515/jbcpp-2025-0089","url":null,"abstract":"<p><strong>Introduction: </strong>Superficial lymph node (LN) enlargement is a common ultrasonographic finding and can be associated with a broad spectrum of conditions, from benign reactive hyperplasia to malignant lymphoproliferative disorders (LPDs). LPDs, which include various hematologic malignancies affecting lymphoid tissue, present with diverse immune-morphological and clinical features, making differentiation from other malignant causes of lymphadenopathy challenging.</p><p><strong>Content: </strong>Radiologic assessment is crucial in characterizing lymphadenopathy, with ultrasonography serving as a noninvasive and widely available imaging modality. High-resolution ultrasound allows the evaluation of key features such as LN size, shape, border definition, echogenicity, and the presence of abnormal cortical thickening, loss of the fatty hilum, or altered vascular patterns, which aid in distinguishing benign from malignant processes.</p><p><strong>Summary: </strong>This review aims to describe the ultrasonographic characteristics of lymphadenopathy, offering essential diagnostic insights to differentiate malignant disorders, particularly LPDs. We will discuss standard ultrasound techniques, including grayscale imaging and Doppler ultrasound, and explore more advanced methods such as contrast-enhanced ultrasound (CEUS), elastography, and artificial intelligence-assisted imaging, which are gaining prominence in LN evaluation.</p><p><strong>Outlook: </strong>By highlighting these imaging modalities, we aim to enhance the diagnostic accuracy of ultrasonography in lymphadenopathy assessment and improve early detection of LPDs and other malignant conditions.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"275-284"},"PeriodicalIF":0.0,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-26eCollection Date: 2025-03-01DOI: 10.1515/jbcpp-2025-0026
Mohammed Bouhajib, Zia Tayab, Chantal Di Marco, Dennis Dong-Kyun Suh
Objectives: In this study, the comparative bioavailability of semaglutide following the administration of oral (PO) and subcutaneous (SC) doses in healthy subjects was evaluated. The pharmacokinetics of semaglutide of these formulations at lower doses (SC dose of 0.25 mg; PO dose of 3 mg) was examined by utilizing a sensitive bioanalytical method.
Methods: Twenty-two subjects were administered either 0.25 mg SC or 3 mg PO and blood samples were taken up to 504 h. The samples were assayed for semaglutide with an analytical range of 0.05-50 ng/mL. The pharmacokinetic parameters were estimated using a non-compartmental approach and were used to evaluate the comparative bioavailability of semaglutide.
Results: The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses. The comparative bioavailability (PO relative to SC) was 0.66 % at the doses administered. Overall, the study drug was well tolerated, and no serious adverse events were reported.
Conclusions: The bioavailability of semaglutide following oral and subcutaneous administrations has been determined using a validated bioanalytical method. This method will enable more investigations into the pharmacokinetics of all formulations of semaglutide at lower doses, which will enable a better understanding of its' disposition in healthy subjects and in patients.
{"title":"The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.","authors":"Mohammed Bouhajib, Zia Tayab, Chantal Di Marco, Dennis Dong-Kyun Suh","doi":"10.1515/jbcpp-2025-0026","DOIUrl":"10.1515/jbcpp-2025-0026","url":null,"abstract":"<p><strong>Objectives: </strong>In this study, the comparative bioavailability of semaglutide following the administration of oral (PO) and subcutaneous (SC) doses in healthy subjects was evaluated. The pharmacokinetics of semaglutide of these formulations at lower doses (SC dose of 0.25 mg; PO dose of 3 mg) was examined by utilizing a sensitive bioanalytical method.</p><p><strong>Methods: </strong>Twenty-two subjects were administered either 0.25 mg SC or 3 mg PO and blood samples were taken up to 504 h. The samples were assayed for semaglutide with an analytical range of 0.05-50 ng/mL. The pharmacokinetic parameters were estimated using a non-compartmental approach and were used to evaluate the comparative bioavailability of semaglutide.</p><p><strong>Results: </strong>The pharmacokinetics of semaglutide was characterized following the administration of low subcutaneous and oral doses. The comparative bioavailability (PO relative to SC) was 0.66 % at the doses administered. Overall, the study drug was well tolerated, and no serious adverse events were reported.</p><p><strong>Conclusions: </strong>The bioavailability of semaglutide following oral and subcutaneous administrations has been determined using a validated bioanalytical method. This method will enable more investigations into the pharmacokinetics of all formulations of semaglutide at lower doses, which will enable a better understanding of its' disposition in healthy subjects and in patients.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"221-227"},"PeriodicalIF":0.0,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144159342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-22eCollection Date: 2025-03-01DOI: 10.1515/jbcpp-2025-0042
Giovanni Salzano, Francesco Maffia, Giovanni Dell'Aversana Orabona
Objectives: This manuscript reviews advancements in oral and maxillofacial surgery, encompassing minimally invasive techniques, innovations in implant dentistry, regenerative medicine, innovations in temporomandibular joint, and novel methodologies in salivary gland surgery.
Methods: A comprehensive analysis of recent developments in the field is presented, focusing on the integration of new technologies and biological therapies. Emphasis is placed on minimally invasive procedures, virtual surgical planning with CAD/CAM and 3D printing, implant design and placement innovations, and regenerative approaches.
Results: Minimally invasive procedures, often employing endoscopic or robotic assistance, reduce surgical morbidity and accelerate patient recovery. Virtual surgical planning and 3D printing enhance pre-surgical accuracy. Innovations in implant design, surface modification, and guided surgery improve prosthetic outcomes. Regenerative medicine and tissue engineering, including the use of growth factors and stem cells, offer new options for tissue restoration. In temporomandibular joint disorders, these strategies aim to improve function and reduce reliance on arthroplasty. The use of superficial dermal substitutes in salivary gland surgery reduces complications such as Frey syndrome.
Conclusions: These advancements reflect a paradigm shift in oral and maxillofacial surgery, enhancing patient care and expanding the field's potential through precision, biologically based therapies, and less invasive approaches.
{"title":"Current trends and innovations in oral and maxillofacial surgery.","authors":"Giovanni Salzano, Francesco Maffia, Giovanni Dell'Aversana Orabona","doi":"10.1515/jbcpp-2025-0042","DOIUrl":"10.1515/jbcpp-2025-0042","url":null,"abstract":"<p><strong>Objectives: </strong>This manuscript reviews advancements in oral and maxillofacial surgery, encompassing minimally invasive techniques, innovations in implant dentistry, regenerative medicine, innovations in temporomandibular joint, and novel methodologies in salivary gland surgery.</p><p><strong>Methods: </strong>A comprehensive analysis of recent developments in the field is presented, focusing on the integration of new technologies and biological therapies. Emphasis is placed on minimally invasive procedures, virtual surgical planning with CAD/CAM and 3D printing, implant design and placement innovations, and regenerative approaches.</p><p><strong>Results: </strong>Minimally invasive procedures, often employing endoscopic or robotic assistance, reduce surgical morbidity and accelerate patient recovery. Virtual surgical planning and 3D printing enhance pre-surgical accuracy. Innovations in implant design, surface modification, and guided surgery improve prosthetic outcomes. Regenerative medicine and tissue engineering, including the use of growth factors and stem cells, offer new options for tissue restoration. In temporomandibular joint disorders, these strategies aim to improve function and reduce reliance on arthroplasty. The use of superficial dermal substitutes in salivary gland surgery reduces complications such as Frey syndrome.</p><p><strong>Conclusions: </strong>These advancements reflect a paradigm shift in oral and maxillofacial surgery, enhancing patient care and expanding the field's potential through precision, biologically based therapies, and less invasive approaches.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"237-240"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-07eCollection Date: 2025-03-01DOI: 10.1515/jbcpp-2025-0037
Giuseppe Di Lorenzo, Carlo Buonerba, Felice Crocetto, Raffaele Baio, Antonio Verde, Vittorino Montanaro, Federica Fortino, Alessia N Calabrese, Concetta Ingenito, Rossella Di Trolio, Serena Rizzano, Armando Pisapia, Vittorio Riccio, Emma Costa, Giovanni Riccio, Carla Errico, Francesco Del Giudice, Antonio Aliberti, Ferdinando Costabile, Giuseppina Busto, Annamaria Libroia, Antonio Coppola, Arcangelo Saggese Tozzi, Oriana Strianese, Luca Scafuri
Objectives: The Sarno river basin (Italy) is a region characterized by significant environmental pollution, raising concerns about heavy metal exposure in residents. The PREVES-STOP Initiative aims to address these concerns. This study investigates the prevalence of detectable blood lead (Pb) and cadmium (Cd) in a cohort of adults from this area and examines associations with key health indicators.
Methods: This study analyzed data from 75 adults (aged 30-65) participating in the PREVES-STOP Initiative. Participants completed comprehensive questionnaires assessing demographics, medical history, lifestyle factors (smoking, physical activity), and psychometric measures (fatigue, anxiety/depression, sleep quality). Blood samples were analyzed for Pb and Cd using established methods, with detectable levels defined as≥2 μg/100 mL (Pb) and ≥0.5 μg/L (Cd).
Results: Detectable Pb (18.67 % of participants) was significantly associated with higher systolic blood pressure, hemoglobin, and MCH, and inversely correlated with HDL cholesterol. Poorer sleep quality was also associated with detectable Pb. Detectable Cd (28 % of participants) was significantly associated with higher systolic blood pressure, LDL cholesterol, neutrophil count, and with higher odds of having a history of autoimmune diseases. Multivariate regression models, adjusting for age, sex, smoking status, and BMI, were used to determine these associations.
Conclusions: This study demonstrates that even low-level exposure to Pb and Cd in the Sarno river basin is associated with adverse clinical outcomes. The PREVES-STOP Initiative provides a valuable framework for community-based health assessment and intervention in areas affected by environmental pollution.
目的:萨尔诺河流域(意大利)是一个环境污染严重的地区,引起了人们对居民重金属暴露的关注。预防-停止倡议旨在解决这些问题。本研究调查了该地区成人队列中可检测血铅(Pb)和镉(Cd)的流行情况,并检查了与关键健康指标的关系。方法:本研究分析了参加prees - stop倡议的75名成年人(30-65岁)的数据。参与者完成了全面的问卷调查,评估人口统计、病史、生活方式因素(吸烟、体育活动)和心理测量指标(疲劳、焦虑/抑郁、睡眠质量)。采用既定方法分析血样中的Pb和Cd,检测水平定义为≥2 μg/100 mL (Pb)和≥0.5 μg/L (Cd)。结果:可检测到的铅(18.67 %的参与者)与较高的收缩压、血红蛋白和MCH显著相关,与高密度脂蛋白胆固醇呈负相关。较差的睡眠质量也与可检测到的铅有关。可检测到的Cd(28% %的参与者)与较高的收缩压、低密度脂蛋白胆固醇、中性粒细胞计数以及具有自身免疫性疾病史的较高几率显著相关。使用多变量回归模型,调整年龄、性别、吸烟状况和BMI来确定这些关联。结论:本研究表明,即使在Sarno河流域低水平暴露于Pb和Cd也与不良临床结果有关。预防-停止倡议为受环境污染影响地区的社区健康评估和干预提供了一个宝贵的框架。
{"title":"Clinical significance of detectable blood lead and cadmium in the Sarno river basin population: results from the PREVES-STOP study.","authors":"Giuseppe Di Lorenzo, Carlo Buonerba, Felice Crocetto, Raffaele Baio, Antonio Verde, Vittorino Montanaro, Federica Fortino, Alessia N Calabrese, Concetta Ingenito, Rossella Di Trolio, Serena Rizzano, Armando Pisapia, Vittorio Riccio, Emma Costa, Giovanni Riccio, Carla Errico, Francesco Del Giudice, Antonio Aliberti, Ferdinando Costabile, Giuseppina Busto, Annamaria Libroia, Antonio Coppola, Arcangelo Saggese Tozzi, Oriana Strianese, Luca Scafuri","doi":"10.1515/jbcpp-2025-0037","DOIUrl":"10.1515/jbcpp-2025-0037","url":null,"abstract":"<p><strong>Objectives: </strong>The Sarno river basin (Italy) is a region characterized by significant environmental pollution, raising concerns about heavy metal exposure in residents. The PREVES-STOP Initiative aims to address these concerns. This study investigates the prevalence of detectable blood lead (Pb) and cadmium (Cd) in a cohort of adults from this area and examines associations with key health indicators.</p><p><strong>Methods: </strong>This study analyzed data from 75 adults (aged 30-65) participating in the PREVES-STOP Initiative. Participants completed comprehensive questionnaires assessing demographics, medical history, lifestyle factors (smoking, physical activity), and psychometric measures (fatigue, anxiety/depression, sleep quality). Blood samples were analyzed for Pb and Cd using established methods, with detectable levels defined as≥2 μg/100 mL (Pb) and ≥0.5 μg/L (Cd).</p><p><strong>Results: </strong>Detectable Pb (18.67 % of participants) was significantly associated with higher systolic blood pressure, hemoglobin, and MCH, and inversely correlated with HDL cholesterol. Poorer sleep quality was also associated with detectable Pb. Detectable Cd (28 % of participants) was significantly associated with higher systolic blood pressure, LDL cholesterol, neutrophil count, and with higher odds of having a history of autoimmune diseases. Multivariate regression models, adjusting for age, sex, smoking status, and BMI, were used to determine these associations.</p><p><strong>Conclusions: </strong>This study demonstrates that even low-level exposure to Pb and Cd in the Sarno river basin is associated with adverse clinical outcomes. The PREVES-STOP Initiative provides a valuable framework for community-based health assessment and intervention in areas affected by environmental pollution.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"203-213"},"PeriodicalIF":0.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-05eCollection Date: 2025-03-01DOI: 10.1515/jbcpp-2025-0005
Abdulbasit Amin, Toyin Mohammed Salman
Glucagon, a key hormone in glucose homeostasis, plays a central role in maintaining blood glucose levels through hepatic glycogenolysis and gluconeogenesis. Historically, glucagon secretion was believed to be primarily regulated by insulin via the "insulin switch-off" hypothesis, where reduced insulin levels triggered glucagon release. However, this view has been revisited as emerging evidence highlights the complexity of glucagon regulation. New studies demonstrate that glucose itself, along with amino acids and fatty acid oxidation, directly influences glucagon secretion, challenging the insulin-centric perspective. These findings reveal the metabolic versatility of pancreatic α-cells and their capacity to adapt to nutrient availability. Recent therapeutic innovations, such as glucagon receptor antagonists, dual GLP-1/glucagon receptor agonists, and modulators of hepatic glucagon signalling, offer promising strategies to mitigate hyperglycemia, improve energy balance, and address metabolic dysregulation. This review provides an in-depth analysis of glucagon's role in health and disease, emphasizing its therapeutic potential in managing diabetes and related metabolic conditions.
{"title":"Glucagon in glucose homeostasis and metabolic disease: from physiology to therapeutics.","authors":"Abdulbasit Amin, Toyin Mohammed Salman","doi":"10.1515/jbcpp-2025-0005","DOIUrl":"10.1515/jbcpp-2025-0005","url":null,"abstract":"<p><p>Glucagon, a key hormone in glucose homeostasis, plays a central role in maintaining blood glucose levels through hepatic glycogenolysis and gluconeogenesis. Historically, glucagon secretion was believed to be primarily regulated by insulin via the \"insulin switch-off\" hypothesis, where reduced insulin levels triggered glucagon release. However, this view has been revisited as emerging evidence highlights the complexity of glucagon regulation. New studies demonstrate that glucose itself, along with amino acids and fatty acid oxidation, directly influences glucagon secretion, challenging the insulin-centric perspective. These findings reveal the metabolic versatility of pancreatic α-cells and their capacity to adapt to nutrient availability. Recent therapeutic innovations, such as glucagon receptor antagonists, dual GLP-1/glucagon receptor agonists, and modulators of hepatic glucagon signalling, offer promising strategies to mitigate hyperglycemia, improve energy balance, and address metabolic dysregulation. This review provides an in-depth analysis of glucagon's role in health and disease, emphasizing its therapeutic potential in managing diabetes and related metabolic conditions.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"139-146"},"PeriodicalIF":0.0,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-04-22eCollection Date: 2025-03-01DOI: 10.1515/jbcpp-2025-0049
Carlo Giulioni, Federico Falsetti, Valentina Maurizi, Francesco Del Giudice, Felice Crocetto, Ciro Imbimbo, Angelo Cafarelli
Introduction: Male infertility is a critical global health issue, with environmental and occupational exposure to heavy metals, such as lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As), impacting male reproductive health. This scoping review aims to evaluate the effects of heavy metal exposure on semen parameters.
Content: This study adhered to the 2020 PRISMA framework. A broad literature search was performed on January 2025, using Embase, PUBMED, and Scopus. A comprehensive literature search was performed using PubMed, Embase, and Scopus on January 12, 2025, using a combination of Medical Subject terms and keywords.
Summary: Of the 1,709 identified studies, 21 met the inclusion criteria and were analyzed. Findings indicate that lead exposure negatively impacts sperm concentration, motility, and morphology, primarily through oxidative stress and enzymatic inhibition. Cadmium disrupts the blood-testis barrier and acrosomal function, leading to sperm abnormalities. Arsenic exposure is linked to oxidative stress, apoptosis, and impaired sperm motility.
Outlook: The cumulative evidence supports a strong association between heavy metal exposure and male infertility. This review underscores the need for stricter occupational safety regulations and environmental policies to mitigate heavy metal exposure.
{"title":"The impact of heavy metals exposure on male fertility: a scoping review of human studies.","authors":"Carlo Giulioni, Federico Falsetti, Valentina Maurizi, Francesco Del Giudice, Felice Crocetto, Ciro Imbimbo, Angelo Cafarelli","doi":"10.1515/jbcpp-2025-0049","DOIUrl":"10.1515/jbcpp-2025-0049","url":null,"abstract":"<p><strong>Introduction: </strong>Male infertility is a critical global health issue, with environmental and occupational exposure to heavy metals, such as lead (Pb), cadmium (Cd), mercury (Hg), and arsenic (As), impacting male reproductive health. This scoping review aims to evaluate the effects of heavy metal exposure on semen parameters.</p><p><strong>Content: </strong>This study adhered to the 2020 PRISMA framework. A broad literature search was performed on January 2025, using Embase, PUBMED, and Scopus. A comprehensive literature search was performed using PubMed, Embase, and Scopus on January 12, 2025, using a combination of Medical Subject terms and keywords.</p><p><strong>Summary: </strong>Of the 1,709 identified studies, 21 met the inclusion criteria and were analyzed. Findings indicate that lead exposure negatively impacts sperm concentration, motility, and morphology, primarily through oxidative stress and enzymatic inhibition. Cadmium disrupts the blood-testis barrier and acrosomal function, leading to sperm abnormalities. Arsenic exposure is linked to oxidative stress, apoptosis, and impaired sperm motility.</p><p><strong>Outlook: </strong>The cumulative evidence supports a strong association between heavy metal exposure and male infertility. This review underscores the need for stricter occupational safety regulations and environmental policies to mitigate heavy metal exposure.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}